|
Regulated information Zwijnaarde - April 8, 2010 In accordance with Article 15 §1 of the Act of May 2, 2007 on the disclosure of major shareholdings, Devgen nv hereby announces the following data: Information as of April 7, 2010: Basic data
| Total share capital (EUR) | 1,475,155.87 | | Total number of securities conferring voting rights | 19,668,776 | | Total number of voting rights (the denominator): | 19,668,776 | | Total number of securities conferring voting rights by category: | N/A | | Total number of voting rights by category | N/A |
Additional facts
| Total number of convertible bonds conferring voting rights | none | | Total number of rights, materialized by certificates or not, to subscribe to not yet issued securities which confer voting rights | 1,555,238 warrants | | Total number of voting rights which result from the exercise of these conversion or subscription rights | 1,555,238 | | Total number of shares without voting rights | none |
About Devgen nv Devgen's mission is to enable farmers to sustainably grow more food on less land, with less water, agrochemicals and labour. Devgen uses advanced biotechnology and molecular breeding technology to make high yielding seeds and crop protection solutions with a superior environmental profile. Devgen brings this technology to the market in the world's major food and feed crops through two complementary strategies: - Licensing Devgen technology for use in corn, cotton and soy and selected other crops in exchange for R&D funding, and milestone and royalty payments. - Producing and selling its premium hybrid seeds in major field crops such as rice, sunflower, sorghum, and pearl millet, in the Indian subcontinent and South-East Asia. In its Crop Protection unit, Devgen developed and has taken to market a novel nematicide, an agro-chemical product that protects crops from damage by parasitic nematodes. Incorporated in 1997, Devgen has offices in Ghent (Belgium), Singapore, Hyderabad (India), General Santos (Phillippines) and Delaware (US) and employs close to 280 people. For more information please contact: | Thierry Bogaert, CEO | Wim Goemaere, CFO | | Tel. +32 9 324 24 24 | Tel. +32 9 324 24 24 | | Thierry.Bogaert@devgen.com | Wim.Goemaere@devgen.com |
Or visit: www.devgen.com This press release may contain forward-looking statements containing the words "anticipates", "expects" , "intends", "plans", "estimates", "may" and "continues" as well as similar expressions. Such forward looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, performance or achievements of Devgen to be materially different from any future results or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: agricultural risks and difficulties, including weather factors, diseases and pests, the costs and requirements of regulatory compliance and the speed with which approvals are received; public acceptance of biotechnology products; political, economic and social developments in countries where Devgen operates and other risks and factors detailed in the company's most recent annual report. These forward looking statements speak only as of the date of publication of this document. Devgen disclaims any obligation to update such forward looking statements in this document to reflect any change in its expectations, conditions or circumstances on which such statement is based, unless required by law or regulation. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any securities issued by Devgen NV.
<< back
|
9052 Ghent-Zwijnaarde, Belgium